CMS Approves NTAP Reimbursement for Molecular Imaging Agent Cytalux
Through a new technology add-on payment (NTAP), the use of Cytalux will reportedly be reimbursed by CMS up to 65 percent of the cost of the molecular imaging agent, which is FDA-approved for intraoperative imaging of ovarian and lung cancer.
What a New MRI Study Reveals About Enhancing Parenchyma in Women with Extremely Dense Breasts
Emerging research suggests that a high volume of enhancing parenchyma on dynamic contrast-enhanced MRI more than doubles the breast cancer risk for women with extremely dense breasts.
Utilizing AI for Quantitative Assessment of Prostate Cancer Recurrence
In a video interview, Hong Song, M.D., Ph.D., discussed retrospective research, presented at the recent Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference, that evaluated the combination of artificial intelligence (AI)-based software and the PSMA agent piflufolastat F 18 to help quantify prostate cancer lesions and associations with biochemical progression-free survival.
CMS Suspends IDR Process of No Surprises Act After Federal Court Vacates IDR Fee Increase
The controversial Independent Dispute Resolution (IDR) process of the No Surprises Act was temporarily suspended by the CMS on August 4 due to a federal court ruling that vacated a substantial administrative fee increase and batching rule from the CMS that reportedly curtailed challenges of claim reimbursement by radiologists and other providers.
Emerging PET Radiotracer May Offer Multiple Advantages in Detecting Prostate Cancer
The PET radiotracer 18F-PSMA-1007 facilitated detection of at least one suspicious lesion for metastasis in nearly half of a cohort of 160 patients with prostate cancer, according to research presented recently at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
CMS Approves NTAP Reimbursement for AI-Powered EchoGo Heart Failure System
In what may represent the first CMS approval of a new technology add-on payment (NTAP) for an artificial intelligence (AI)-based heart failure detection platform, use of the EchoGo Heart Failure system will be eligible for up to $1,023.75 in NTAP reimbursement per acute hospital in-patient stay as of October 1, 2023.
Emerging Concepts with ICM Reduction and Photon Counting for Coronary CT Angiography
Emerging research suggests that achieving an optimal virtual monoenergetic image (VMI) energy level with photon-counting computed tomography (CT) may allow up to a 40 percent reduction of contrast media dosing for coronary CT angiography.
Large Mammography Study Shows Significant Benefits with AI-Aided Screening
Reportedly the first randomized trial to examine the impact of artificial intelligence (AI) on screening mammography, researchers found AI-aided screening led to a 20 percent increase in breast cancer detection and a 44.3 percent decrease in mammography screening workload.
Study: Combination of Ultrasound and MRI-Targeted Biopsy Enhances Detection of Prostate Cancer
In a study of 413 men with suspected prostate cancer, researchers found the combination of ultrasound and multiparametric MRI-targeted biopsy with systematic biopsy diagnosed prostate cancer in 72.9 percent of patients in comparison to 60.2 percent with systematic biopsy alone.
Aidoc Launches AI-Powered Neuroimaging Software for Vessel Occlusion Detection on CT
Full Brain Solution is reportedly the only artificial intelligence (AI)-enabled software that facilitates detection of medium vessel occlusions (MeVOs) as well as anterior and posterior large vessel occlusions (LVOs) on computed tomography (CT) exams.